SEC Filing Analysis: GILEAD SCIENCES, INC. (GILD)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer exercised stock options and sold the resulting shares for a total of $6.6M under a pre-scheduled 10b5-1 trading plan.
• Market Impact: The transaction is considered routine for a large-cap company and is unlikely to have a material impact on the stock price.

Company Information

Field	Value
Company	GILEAD SCIENCES, INC.
Ticker Symbol	GILD
CIK	0000882095
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Telman Deborah H
CIK	0001860008
Title/Position	EVP, Corporate Affairs & GC
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-12
Transaction Code	S / M
Security Type	Common Stock
Shares Involved	53,646 (Sold)
Price Per Share	~$122.85 (Weighted Average Sale Price)
Total Value	$6,590,506
Shares Owned After	43,676
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$6,590,506
% of Market Cap	0.0045%
Shares Transacted	53,646
% of Shares Outstanding	0.0043%
Post-Transaction Ownership	43,676 shares (0.0035% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a mega-cap company like Gilead with a market capitalization of $146.59 billion, a $6.6 million transaction is financially immaterial.
• Ownership Concentration: The insider's post-transaction ownership of 43,676 shares represents a very small fraction of the total shares outstanding, indicating low ownership concentration from this individual.
• Dilution Impact: The transaction involved the exercise of previously granted options, which was already factored into the company's diluted share count. The immediate sale negates any change in the insider's long-term holdings from this event.
• Transaction Significance: The sale represents a very small percentage of both market cap (<0.1%) and shares outstanding (<0.1%), classifying its significance as Low. The pre-scheduled nature of the trade further reduces its informational value.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is a non-discretionary sale executed under a Rule 10b5-1 plan. Such sales are common for executive compensation and are not typically interpreted as a change in the insider's outlook on the company.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is insignificant compared to Gilead's average daily trading volume.
• Sentiment Indicator: Neutral. The market generally disregards pre-planned sales for compensation purposes.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. This indicates the sales were pre-scheduled and not based on any immediate, private information.